A Phase 3 interventional study of Folate and Methotrexate in Rheumatoid Arthritis, sponsored by Genentech, Inc.. Completed. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2017-04-17.
Sponsored by Genentech, Inc. (part of Hoffmann-La Roche) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 113 studies testing methotrexate in Arthritis, Rheumatoid — 8 open to participants now, 10 under way, 2 of them phase 3. Methotrexate · Arthritis, Rheumatoid.
Among the 113 studies testing methotrexate in Arthritis, Rheumatoid, this one is the 14th largest by enrollment, is one of 6 that started in 2005, is one of 47 in phase 3, and was the 13th registered.
3,335 studies on the registry are indexed under Arthritis, Rheumatoid; 445 are open to participants now.
Browse Arthritis, Rheumatoid studies →8 of the 113 studies testing methotrexate in Arthritis, Rheumatoid are open now, in 5 countries. Recruiting first, the newest first:
NYU Langone Health · Sites in United States
Ages 18+
Keio University · Sites in Japan
Ages 18+
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University · Sites in China
Ages 18–65
Konkuk University Medical Center · Sites in Korea, Republic of
Ages 19+
Medical University of Vienna · Sites in Austria
Ages 18–99
By country, each count listing its studies:
Methotrexate: first FDA approval 1953 (METHOTREXATE SODIUM), first EMA approval 2016. What it is approved for, and how studies give it, is on its page →
Of the 293 Arthritis, Rheumatoid studies recruiting now, 150 (51%) set no upper age limit and 109 (37%) stop at 75 or younger; 15 take children under 18; 36 take healthy volunteers.
This study: 18 Years to 80 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
113 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 13 · Phase 2 12 · Phase 3 48 · Phase 4 38
First in 1998; this study’s year is marked. 6 started in 2005.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 511 is above the median of 96 across 2,223 interventional studies indexed under Arthritis, Rheumatoid.
Median enrollment 130 across the 113 interventional studies. Of the 93 that completed or were terminated, 58 (62%) have results posted.
This tab as a report to print or save as PDF → With an account.
84 of 113 have an industry lead sponsor. The 10 most frequent:
This study is registered under Genentech, Inc., one of the names counted as Hoffmann-La Roche. Under that name alone:
Genentech, Inc. is the lead sponsor of 517 studies on the registry; 20 are open to participants now.
Of its 95 completed or terminated interventional studies of FDA-regulated products, 52 (55%) have results posted.
219 studies in Arthritis, Rheumatoid by Hoffmann-La Roche: 2 open now, 2 under way, none of them phase 3. Of 214 finished, 139 (65%) have results posted.
Among the 219 studies in Arthritis, Rheumatoid by Hoffmann-La Roche, this one is the 26th largest by enrollment of the 141 interventional ones that give a count, is one of 14 that started in 2005, is one of 85 in phase 3, and was the 20th registered.
Hoffmann-La Roche’s Arthritis, Rheumatoid studies by the year they started, since 2001.
3 of the studies testing methotrexate in Arthritis, Rheumatoid that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05353829Region VästerbottenMethotrexate in Patients with Early Rheumatoid Arthritis | 2026-12-31 |
| NCT06590090XBiotech, Inc.Natrunix in Combination With Methotrexate for Rheumatoid Arthritis Treatment | 2027-01-15 |
| NCT06649136Medical University of ViennaMethMax Trial: MAXimising the METHotrexate Therapy Potential in Patients With Active Rheumatoid Arthritis | 2027-06-07 |
Add all 3 to your calendar (.ics) → With an account.
Among the 113 studies testing methotrexate in Arthritis, Rheumatoid, from their registry updates:
Among Hoffmann-La Roche’s 219 in Arthritis, Rheumatoid:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This study evaluated the efficacy and safety of rituximab in patients with active rheumatoid arthritis (RA).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
At screening, either
Exclusion criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants received placebo intravenous infusion on Days 1 and 15. From Week 16 onwards, participants could switch to receive rituximab 0.5 g (on Days 1 and 15) every 24 weeks for up to 5 years if they were not in clinical remission and safety criteria were met. Placebo and rituximab infusions were preceded with 100 milligrams (mg) intravenous methylprednisolone. Participants also received a stable dose of 10-25 mg/week of MTX and ≥ 5 mg/week folic acid for the duration of their participation in the study. All participants entered a 48-week safety follow-up (SFU) period following the treatment period.
Drug: Folate · Drug: Methotrexate · Drug: Methylprednisolone · Drug: Placebo · Drug: Rituximab
Participants received 0.5 g rituximab administered by intravenous infusion on Days 1 and 15. After Week 24, participants received further courses of rituximab every 24 weeks for up to 5 years if they were not in clinical remission and safety criteria were met. Rituximab infusions were preceded with 100 mg intravenous methylprednisolone. Participants also received a stable dose of 10-25 mg/week of methotrexate and ≥ 5 mg/week folic acid for the duration of their participation in the study. All participants entered a 48-week safety follow-up (SFU) period following the treatment period.
Drug: Folate · Drug: Methotrexate · Drug: Methylprednisolone · Drug: Rituximab
Participants received 1.0 g rituximab administered by intravenous infusion on Days 1 and 15. After Week 24, participants received further courses of rituximab every 24 weeks for up to 5 years if they were not in clinical remission and safety criteria were met. Rituximab infusions were preceded with 100 mg intravenous methylprednisolone. Participants also received a stable dose of 10-25 mg/week of methotrexate and ≥ 5 mg/week folic acid for the duration of their participation in the study. All participants entered a 48-week safety follow-up (SFU) period following the treatment period.
Drug: Folate · Drug: Methotrexate · Drug: Methylprednisolone · Drug: Rituximab
A stable dose, ≥ 5 mg/week given as either a single dose or as a divided weekly dose, orally.
A stable dose of between 10-25 mg/week, oral or parenteral, as prescribed by the treating physician.
Intravenous infusion
Placebo to rituximab intravenous infusion
Intravenous infusion
Also known as: MabThera®, Rituxan®
Percentage of Participants With American College of Rheumatology (ACR) 20 Response at Week 24
To achieve an ACR20 required at least a 20% improvement compared with Baseline in both tender joint counts (68 joints assessed for tenderness) and swollen joint counts (66 joints assessed for swelling), as well as a 20% improvement in three of the following five additional measurements: * Physician's global assessment of disease activity (assessed using a 100 mm Visual Analog Scale \[VAS\]); * Patient's global assessment of disease activity (assessed using a 100 mm VAS); * Patient's assessment of pain (assessed using a 100 mm VAS); * Health Assessment Questionnaire (HAQ; a patient completed questionnaire consisting of 20 questions, scored from 0-3); * Acute phase reactant: C-reactive protein (CRP) or, if CRP was missing, erythrocyte sedimentation rate (ESR). Participants who withdrew prematurely from the study prior to Week 24, who received rescue therapy or had insufficient data in order to calculate a clinical response were considered to be non-responders.
Time frame: Baseline and Week 24
Percentage of Participants With an ACR50 Response at Week 24
To achieve an ACR50 required at least a 50% improvement compared with Baseline in both tender joint counts (68 joints assessed for tenderness) and swollen joint counts (66 joints assessed for swelling), as well as a 50% improvement in three of the following five additional measurements: * Physician's global assessment of disease activity (assessed using a 100 mm Visual Analog Scale \[VAS\]); * Patient's global assessment of disease activity (assessed using a 100 mm VAS); * Patient's assessment of pain (assessed using a 100 mm VAS); * Health Assessment Questionnaire (HAQ; a patient completed questionnaire consisting of 20 questions, scored from 0-3); * Acute phase reactant: C-reactive protein (CRP) or, if CRP was missing, erythrocyte sedimentation rate (ESR). Participants who withdrew prematurely from the study prior to Week 24, who received rescue therapy or had insufficient data in order to calculate a clinical response were considered to be non-responders.
Time frame: Baseline and Week 24
Percentage of Participants With an ACR70 Response at Week 24
To achieve an ACR70 required at least a 70% improvement compared with Baseline in both tender joint counts (68 joints assessed for tenderness) and swollen joint counts (66 joints assessed for swelling), as well as a 70% improvement in three of the following five additional measurements: * Physician's global assessment of disease activity (assessed using a 100 mm Visual Analog Scale \[VAS\]); * Patient's global assessment of disease activity (assessed using a 100 mm VAS); * Patient's assessment of pain (assessed using a 100 mm VAS); * Health Assessment Questionnaire (HAQ; a patient completed questionnaire consisting of 20 questions, scored from 0-3); * Acute phase reactant: C-reactive protein (CRP) or, if CRP was missing, erythrocyte sedimentation rate (ESR). Participants who withdrew prematurely from the study prior to Week 24, who received rescue therapy or had insufficient data in order to calculate a clinical response were considered to be non-responders.
Time frame: Baseline and Week 24
Change From Baseline in Disease Activity Score (DAS28-ESR) at Week 24
The DAS28 is a composite score to measure disease activity in patients with rheumatoid arthritis, derived from the following variables: * The number of swollen and tender joints assessed using the 28-joint count; * Erythrocyte sedimentation rate (ESR); * Patient's global assessment of disease activity measured on a 100 mm visual analog scale. The DAS28 score ranges from zero to ten. A DAS28 score above 5.1 means high disease activity whereas a DAS28 less than or equal to 3.2 indicates low disease activity. Remission is achieved by a DAS28 lower than 2.6.
Time frame: Baseline and Week 24
Percentage of Participants With European League Against Rheumatism (EULAR) Response at Week 24
A EULAR response reflects an improvement in disease activity and an attainment of a lower degree of disease activity based on the DAS28 score. The DAS28 score ranges from 0-10, with higher scores indicating more disease activity. A Good Response is defined as an improvement (decrease) in the DAS28 of more than 1.2 compared with Baseline and attainment of a DAS28 score of less than or equal to 3.2. A Moderate Response is defined as either: * an improvement (decrease) in the DAS28 of greater than 0.6 and less than or equal to 1.2 from Baseline and attainment of a DAS28 score of less than or equal to 5.1 or, * an improvement (decrease) in the DAS28 of more than 1.2 from Baseline and attainment of a DAS28 score of greater than 3.2. No Response is defined as either an improvement (decrease) in the DAS28 of less than or equal to 0.6, or an improvement (decrease) in the DAS28 of greater than 0.6 and less than or equal to 1.2 and attainment of a DAS28 of more than 5.1.
Time frame: Baseline and Week 24
Percent Change From Baseline in Swollen Joint Count
Sixty-six joints were assessed and classified as swollen/not swollen by pressure and joint manipulation on physical examination. The percentage change from baseline at each post-baseline visit was calculated as: \[(post-baseline value minus baseline value) divided by Baseline value\]\*100. A negative percentage change from baseline score indicates an improvement.
Time frame: Baseline, Week 24 and Week 48
Percent Change From Baseline in Tender Joint Count
Sixty-eight joints were assessed and classified as tender/not tender by pressure and joint manipulation on physical examination. The percentage change from baseline at each post-baseline visit was calculated as: \[(post-baseline value minus baseline value) divided by Baseline value\]\*100. A negative percentage change from baseline score indicates an improvement.
Time frame: Baseline, Week 24 and Week 48
Percent Change From Baseline in Patient's Global Assessment of Disease Activity
The participant's overall assessment of their current disease activity measured on a 100 mm horizontal visual analog scale (VAS). The left-hand extreme of the line (0 mm) was described as "no disease activity" (symptom-free and no arthritis symptoms) and the right-hand extreme (100 mm) as "maximum disease activity" (maximum arthritis disease activity). The percentage change from baseline at each post-baseline visit was calculated as: \[(post-baseline value minus baseline value) divided by Baseline value\]\*100. A negative percentage change from baseline score indicates an improvement.
Time frame: Baseline, Week 24 and Week 48
Percent Change From Baseline in Patient's Pain Assessment
The participant's assessment of their current level of pain on a 100 mm horizontal visual analog scale (VAS), where the left-hand extreme of the line (0 mm) was described as "no pain" and the right-hand extreme (100 mm) as "unbearable pain". The percentage change from baseline at each post-baseline visit was calculated as: \[(post-baseline value minus baseline value) divided by Baseline value\]\*100. A negative percentage change from baseline score indicates an improvement.
Time frame: Baseline, Week 24 and Week 48
Percent Change From Baseline in Physician's Global Assessment of Disease Activity
The physician's assessment of the participant's current disease activity on a 100 mm horizontal VAS, where the left-hand extreme of the line (0 mm) was described as "no disease activity" (symptom-free and no arthritis symptoms) and the right-hand extreme (100 mm) as "maximum disease activity". The percentage change from baseline at each post-baseline visit was calculated as: \[(post-baseline value minus baseline value) divided by Baseline value\]\*100. A negative percentage change from baseline score indicates an improvement.
Time frame: Baseline, Week 24 and Week 48
Percent Change From Baseline in Health Assessment Questionnaire Disability Index (HAQ-DI) Score
The Stanford Health Assessment Questionnaire disability index is a patient-reported questionnaire specific for rheumatoid arthritis. It consists of 20 questions referring to eight domains: dressing/grooming, arising, eating, walking, hygiene, reach, grip, and daily activities. Participants choose from four response categories, ranging from 'without any difficulty' (Score=0) to 'unable to do' (Score=3). The overall score is the average of each of the 8 category scores and ranges from 0 to 3, where zero represents no disability and three very severe, high-dependency disability. The percentage change from baseline at each post-baseline visit was calculated as: \[(post-baseline value minus baseline value) divided by Baseline value\]\*100. A negative percentage change from baseline score indicates an improvement.
Time frame: Baseline, Week 24 and Week 48
Percent Change From Baseline in C-Reactive Protein
C-Reactive Protein (CRP) was measured from blood samples by a central laboratory as a marker for inflammation. The percentage change from baseline at each post-baseline visit was calculated as: \[(post-baseline value minus baseline value) divided by Baseline value\]\*100. A negative percentage change from baseline score indicates an improvement.
Time frame: Baseline, Week 24 and Week 48
Percent Change From Baseline in Erythrocyte Sedimentation Rate
Erythrocyte sedimentation rate (ESR) indirectly measures how much inflammation is in the body. A higher ESR is indicative of increased inflammation. The percentage change from baseline at each post-baseline visit was calculated as: \[(post-baseline value minus baseline value) divided by Baseline value\]\*100. A negative percentage change from baseline score indicates an improvement.
Time frame: Baseline, Week 24 and Week 48
Percent Change From Baseline in Short Form 36 Health Survey (SF-36) Summary Scores (Physical and Mental Components)
The SF-36 measures the impact of disease on overall quality of life and consists of 36 questions split into two major components: physical health and mental health. Under physical health are the following four domains: physical health, bodily pain, physical functioning and physical role limitations. Under the mental health domain there are four domains; mental health, vitality, social functioning, and emotional role limitation. The individual domain scores are aggregated to derive a physical-component summary score and a mental-component summary score which range from 0 to 100, with higher scores indicating a better level of functioning. The percentage change from baseline at each post-baseline visit was calculated as: \[(post-baseline value minus baseline value) divided by Baseline value\]\*100. A positive percentage change from baseline score indicates an improvement.
Time frame: Baseline, Week 24 and Week 48
Change From Baseline in Short Form 36 Health Survey (SF-36) General Health Domain Score
The SF-36 measures the impact of disease on overall quality of life and consists of 36 questions in eight domains (physical function, pain, general and mental health, vitality, social function, physical and emotional health). The individual domain scores are calculated and transformed to range from 0 to 100, with higher scores indicating a better level of functioning. A positive change from baseline score indicates an improvement.
Time frame: Baseline, Week 24 and Week 48
Change From Baseline in Short Form 36 Health Survey (SF-36) Bodily Pain Domain Score
The SF-36 measures the impact of disease on overall quality of life and consists of 36 questions in eight domains (physical function, pain, general and mental health, vitality, social function, physical and emotional health). The individual domain scores are calculated and transformed to range from 0 to 100, with higher scores indicating a better level of functioning. A positive change from baseline score indicates an improvement.
Time frame: Baseline, Week 24 and Week 48
Change From Baseline in Short Form 36 Health Survey (SF-36) Physical Functioning Domain Score
The SF-36 measures the impact of disease on overall quality of life and consists of 36 questions in eight domains (physical function, pain, general and mental health, vitality, social function, physical and emotional health). The individual domain scores are calculated and transformed to range from 0 to 100, with higher scores indicating a better level of functioning. A positive change from baseline score indicates an improvement.
Time frame: Baseline, Week 24 and Week 48
Change From Baseline in Short Form 36 Health Survey (SF-36) Physical Role Limitations Domain Score
The SF-36 measures the impact of disease on overall quality of life and consists of 36 questions in eight domains (physical function, pain, general and mental health, vitality, social function, physical and emotional health). The individual domain scores are calculated and transformed to range from 0 to 100, with higher scores indicating a better level of functioning. A positive change from baseline score indicates an improvement.
Time frame: Baseline, Week 24 and Week 48
Change From Baseline in Short Form 36 Health Survey (SF-36) Mental Health Domain Score
The SF-36 measures the impact of disease on overall quality of life and consists of 36 questions in eight domains (physical function, pain, general and mental health, vitality, social function, physical and emotional health). The individual domain scores are calculated and transformed to range from 0 to 100, with higher scores indicating a better level of functioning. A positive change from baseline score indicates an improvement.
Time frame: Baseline, Week 24 and Week 48
Change From Baseline in Short Form 36 Health Survey (SF-36) Vitality Domain Score
The SF-36 measures the impact of disease on overall quality of life and consists of 36 questions in eight domains (physical function, pain, general and mental health, vitality, social function, physical and emotional health). The individual domain scores are calculated and transformed to range from 0 to 100, with higher scores indicating a better level of functioning. A positive change from baseline score indicates an improvement.
Time frame: Baseline, Week 24 and Week 48
Change From Baseline in Short Form 36 Health Survey (SF-36) Social Functioning Domain Score
The SF-36 measures the impact of disease on overall quality of life and consists of 36 questions in eight domains (physical function, pain, general and mental health, vitality, social function, physical and emotional health). The individual domain scores are calculated and transformed to range from 0 to 100, with higher scores indicating a better level of functioning. A positive change from baseline score indicates an improvement.
Time frame: Baseline, Week 24 and Week 48
Change From Baseline in Short Form 36 Health Survey (SF-36) Emotional Role Limitations Domain Score
The SF-36 measures the impact of disease on overall quality of life and consists of 36 questions in eight domains (physical function, pain, general and mental health, vitality, social function, physical and emotional health). The individual domain scores are calculated and transformed to range from 0 to 100, with higher scores indicating a better level of functioning. A positive change from baseline score indicates an improvement.
Time frame: Baseline, Week 24 and Week 48
Change From Baseline in Functional Assessment of Chronic Illness Therapy - Fatigue (FACIT-F) Scores
The FACIT-Fatigue questionnaire is a self-administered patient questionnaire that consists of 13 questions designed to measure the degree of fatigue experienced by participants in the previous 7 days. Participants respond to the questions using a value in the range of 0 (not at all) to 4 (very much). The scale score is computed by summing the item scores, after reversing those items that are worded in the negative direction. The FACIT-Fatigue subscale score ranges from 0 to 52, where higher scores represent less fatigue. A positive change from baseline score indicates an improvement.
Time frame: Baseline, Week 24 and Week 48
Percentage of Participants With DAS28-ESR Low Disease Activity Score and Clinical Remission at Week 24
The DAS28 is a composite score to measure disease activity in patients with rheumatoid arthritis, derived from the following variables: * The number of swollen and tender joints assessed using the 28-joint count; * Erythrocyte sedimentation rate (ESR); * Patient's global assessment of disease activity measured on a 100 mm visual analog scale. The DAS28 score ranges from zero to ten. DAS28 above 5.1 indicates high disease activity. Low disease activity is defined by a DAS28 score less than or equal to 3.2. Remission is defined by a DAS28 score less than 2.6.
Time frame: Week 24
Percentage of Participants With HAQ-DI Improved, Unchanged or Worsened at Week 24
The Stanford Health Assessment Questionnaire disability index is a patient-reported questionnaire specific for rheumatoid arthritis. It consists of 20 questions referring to eight domains: dressing/grooming, arising, eating, walking, hygiene, reach, grip, and daily activities. Participants choose from four response categories, ranging from 'without any difficulty' (Score=0) to 'unable to do' (Score=3). The overall score is the average of each of the 8 category scores and ranges from 0 to 3, where zero represents no disability and three very severe, high-dependency disability. A negative change from baseline score indicates an improvement. Improved HAQ-DI is defined as a change from Baseline score less than or equal to -0.22. An Unchanged HAQ-DI is defined as a change from Baseline score greater than -0.22 and less than 0.22. A worsened HAQ-DI score is defined as a change from Baseline score of greater than or equal to 0.22.
Time frame: Baseline and Week 24
Percentage of Participants With HAQ-DI Improved, Unchanged or Worsened at Week 48
The Stanford Health Assessment Questionnaire disability index is a patient-reported questionnaire specific for rheumatoid arthritis. It consists of 20 questions referring to eight domains: dressing/grooming, arising, eating, walking, hygiene, reach, grip, and daily activities. Participants choose from four response categories, ranging from 'without any difficulty' (Score=0) to 'unable to do' (Score=3). The overall score is the average of each of the 8 category scores and ranges from 0 to 3, where zero represents no disability and three very severe, high-dependency disability. A negative change from baseline score indicates an improvement. Improved HAQ-DI is defined as a change from Baseline score less than or equal to -0.22. An Unchanged HAQ-DI is defined as a change from Baseline score greater than -0.22 and less than 0.22. A worsened HAQ-DI score is defined as a change from Baseline score of greater than or equal to 0.22.
Time frame: Baseline and Week 48
Percentage of Participants With European League Against Rheumatism (EULAR) Response at Week 48
A EULAR response reflects an improvement in disease activity and an attainment of a lower degree of disease activity based on the DAS-28 score. A Good Response is defined as an improvement (decrease) in the DAS28 of more than 1.2 compared with Baseline and attainment of a DAS28 score less than or equal to 3.2. A Moderate Response is defined as either: * an improvement (decrease) in the DAS28 of greater than 0.6 and less than or equal to 1.2 and attainment of a DAS28 score of less than or equal to 5.1 or, * an improvement (decrease) in the DAS28 of more than 1.2 and attainment of a DAS28 score of greater than 3.2. No Response is defined as either an improvement (decrease) in the DAS28 of less than or equal to 0.6, or an improvement (decrease) in the DAS28 of greater than 0.6 and less than or equal to 1.2 and attainment of a DAS28 score of 5.1 or higher.
Time frame: Baseline and Week 48
Percentage of Participants With DAS28-ESR Low Disease Activity Score and Clinical Remission at Week 48
The DAS28 is a composite score to measure disease activity in patients with rheumatoid arthritis, derived from the following variables: * The number of swollen and tender joints assessed using the 28-joint count; * Erythrocyte sedimentation rate (ESR); * Patient's global assessment of disease activity measured on a 100 mm visual analog scale. The DAS28 score ranges from zero to ten. DAS28 above 5.1 indicates high disease activity. Low disease activity is defined by a DAS28 score less than or equal to 3.2. Remission is defined by a DAS28 score less than 2.6.
Time frame: Week 48
Percentage of Participants With an ACR50 Response at Week 48
To achieve an ACR50 required at least a 50% improvement compared with Baseline in both tender joint counts (68 joints assessed for tenderness) and swollen joint counts (66 joints assessed for swelling), as well as a 50% improvement in three of the following five additional measurements: * Physician's global assessment of disease activity (assessed using a 100 mm Visual Analog Scale \[VAS\]); * Patient's global assessment of disease activity (assessed using a 100 mm VAS); * Patient's assessment of pain (assessed using a 100 mm VAS); * Health Assessment Questionnaire (HAQ; a patient completed questionnaire consisting of 20 questions, scored from 0-3); * Acute phase reactant: C-reactive protein (CRP) or, if CRP was missing, erythrocyte sedimentation rate (ESR). Participants who withdrew prematurely from the study prior to week 48, who received rescue therapy or had insufficient data in order to calculate a clinical response were considered to be non-responders.
Time frame: Baseline and Week 48
Percentage of Participants With an ACR70 Response at Week 48
To achieve an ACR70 required at least a 70% improvement compared with baseline in both tender joint counts (68 joints assessed for tenderness) and swollen joint counts (66 joints assessed for swelling), as well as a 70% improvement in three of the following five additional measurements: * Physician's global assessment of disease activity (assessed using a 100 mm Visual Analog Scale \[VAS\]); * Patient's global assessment of disease activity (assessed using a 100 mm VAS); * Patient's assessment of pain (assessed using a 100 mm VAS); * Health Assessment Questionnaire (HAQ; a patient completed questionnaire consisting of 20 questions, scored from 0-3); * Acute phase reactant: C-reactive protein (CRP) or, if CRP was missing, erythrocyte sedimentation rate (ESR). Participants who withdrew prematurely from the study prior to Week 48, who received rescue therapy or had insufficient data in order to calculate a clinical response were considered to be non-responders.
Time frame: Baseline and Week 48
A total of 511 participants were recruited and randomized between 27 Oct 2005 and 15 Nov 2006. Of these, 2 participants were randomized but received no infusions (one violated inclusion criteria and the other was randomized to rituximab 2 x 1.0 gram \[g\] + methotrexate \[MTX\] but failed to return). A total of 509 participants were treated.
| Milestone | Placebo + MTX | Rituximab 2 x 0.5 g + MTX | Rituximab 2 x 1.0 g + MTX |
|---|---|---|---|
| Started | 172 | 168 | 171 |
| Treated | 172 | 167 | 170 |
| Completed 24 weeks | 159 | 162 | 166 |
| Completed 48 weeks | 155 | 157 | 158 |
| Completed 144 weeks | 133 | 138 | 132 |
| Completed | 119 | 125 | 121 |
| Not completed | 53 | 43 | 50 |
| Withdrew: Adverse event | 13 | 8 | 13 |
| Withdrew: Death | 1 | 3 | 1 |
| Withdrew: Insufficient therapeutic response | 19 | 6 | 6 |
| Withdrew: Protocol violation | 0 | 1 | 0 |
| Withdrew: Refused treatment | 12 | 12 | 19 |
| Withdrew: Failure to return | 4 | 6 | 6 |
| Withdrew: Reason not specified | 4 | 6 | 4 |
| Withdrew: Withdrawal by subject | 0 | 1 | 1 |
| Milestone | Placebo + MTX | Rituximab 2 x 0.5 g + MTX | Rituximab 2 x 1.0 g + MTX |
|---|---|---|---|
| Started | 167 | 165 | 168 |
| Completed | 122 | 120 | 123 |
| Not completed | 45 | 45 | 45 |
| Withdrew: Administrative/other | 4 | 9 | 4 |
| Withdrew: Death | 4 | 5 | 3 |
| Withdrew: Did not co-operate | 1 | 1 | 2 |
| Withdrew: Failure to return | 14 | 7 | 15 |
| Withdrew: No sfu week 48 date recorded | 0 | 1 | 0 |
| Withdrew: Withdrawal by subject | 22 | 22 | 21 |
| Milestone | Placebo + MTX | Rituximab 2 x 0.5 g + MTX | Rituximab 2 x 1.0 g + MTX |
|---|---|---|---|
| Started | 0 | 82 | 44 |
| Completed | 0 | 74 | 38 |
| Not completed | 0 | 8 | 6 |
| Withdrew: Death | 0 | 3 | 0 |
| Withdrew: Failure to return | 0 | 2 | 2 |
| Withdrew: Did not cooperate/withdrew consent | 0 | 3 | 4 |
To achieve an ACR20 required at least a 20% improvement compared with Baseline in both tender joint counts (68 joints assessed for tenderness) and swollen joint counts (66 joints assessed for swelling), as well as a 20% improvement in three of the following five additional measurements: * Physician's global assessment of disease activity (assessed using a 100 mm Visual Analog Scale \[VAS\]); * Patient's global assessment of disease activity (assessed using a 100 mm VAS); * Patient's assessment of pain (assessed using a 100 mm VAS); * Health Assessment Questionnaire (HAQ; a patient completed questionnaire consisting of 20 questions, scored from 0-3); * Acute phase reactant: C-reactive protein (CRP) or, if CRP was missing, erythrocyte sedimentation rate (ESR). Participants who withdrew prematurely from the study prior to Week 24, who received rescue therapy or had insufficient data in order to calculate a clinical response were considered to be non-responders.
| percentage of participants | Placebo + MTX | Rituximab 2 x 0.5 g + MTX | Rituximab 2 x 1.0 g + MTX |
|---|---|---|---|
| Percentage of Participants With American College of Rheumatology (ACR) 20 Response at Week 24 | 23.3 | 54.5 | 50.6 |
To achieve an ACR50 required at least a 50% improvement compared with Baseline in both tender joint counts (68 joints assessed for tenderness) and swollen joint counts (66 joints assessed for swelling), as well as a 50% improvement in three of the following five additional measurements: * Physician's global assessment of disease activity (assessed using a 100 mm Visual Analog Scale \[VAS\]); * Patient's global assessment of disease activity (assessed using a 100 mm VAS); * Patient's assessment of pain (assessed using a 100 mm VAS); * Health Assessment Questionnaire (HAQ; a patient completed questionnaire consisting of 20 questions, scored from 0-3); * Acute phase reactant: C-reactive protein (CRP) or, if CRP was missing, erythrocyte sedimentation rate (ESR). Participants who withdrew prematurely from the study prior to Week 24, who received rescue therapy or had insufficient data in order to calculate a clinical response were considered to be non-responders.
| percentage of participants | Placebo + MTX | Rituximab 2 x 0.5 g + MTX | Rituximab 2 x 1.0 g + MTX |
|---|---|---|---|
| Percentage of Participants With an ACR50 Response at Week 24 | 9.3 | 26.3 | 25.9 |
To achieve an ACR70 required at least a 70% improvement compared with Baseline in both tender joint counts (68 joints assessed for tenderness) and swollen joint counts (66 joints assessed for swelling), as well as a 70% improvement in three of the following five additional measurements: * Physician's global assessment of disease activity (assessed using a 100 mm Visual Analog Scale \[VAS\]); * Patient's global assessment of disease activity (assessed using a 100 mm VAS); * Patient's assessment of pain (assessed using a 100 mm VAS); * Health Assessment Questionnaire (HAQ; a patient completed questionnaire consisting of 20 questions, scored from 0-3); * Acute phase reactant: C-reactive protein (CRP) or, if CRP was missing, erythrocyte sedimentation rate (ESR). Participants who withdrew prematurely from the study prior to Week 24, who received rescue therapy or had insufficient data in order to calculate a clinical response were considered to be non-responders.
| percentage of participants | Placebo + MTX | Rituximab 2 x 0.5 g + MTX | Rituximab 2 x 1.0 g + MTX |
|---|---|---|---|
| Percentage of Participants With an ACR70 Response at Week 24 | 5.2 | 9.0 | 10.0 |
The DAS28 is a composite score to measure disease activity in patients with rheumatoid arthritis, derived from the following variables: * The number of swollen and tender joints assessed using the 28-joint count; * Erythrocyte sedimentation rate (ESR); * Patient's global assessment of disease activity measured on a 100 mm visual analog scale. The DAS28 score ranges from zero to ten. A DAS28 score above 5.1 means high disease activity whereas a DAS28 less than or equal to 3.2 indicates low disease activity. Remission is achieved by a DAS28 lower than 2.6.
| scores on a scale | Placebo + MTX | Rituximab 2 x 0.5 g + MTX | Rituximab 2 x 1.0 g + MTX |
|---|---|---|---|
| Change From Baseline in Disease Activity Score (DAS28-ESR) at Week 24 | -0.76 ± 1.304 | -1.71 ± 1.334 | -1.68 ± 1.342 |
A EULAR response reflects an improvement in disease activity and an attainment of a lower degree of disease activity based on the DAS28 score. The DAS28 score ranges from 0-10, with higher scores indicating more disease activity. A Good Response is defined as an improvement (decrease) in the DAS28 of more than 1.2 compared with Baseline and attainment of a DAS28 score of less than or equal to 3.2. A Moderate Response is defined as either: * an improvement (decrease) in the DAS28 of greater than 0.6 and less than or equal to 1.2 from Baseline and attainment of a DAS28 score of less than or equal to 5.1 or, * an improvement (decrease) in the DAS28 of more than 1.2 from Baseline and attainment of a DAS28 score of greater than 3.2. No Response is defined as either an improvement (decrease) in the DAS28 of less than or equal to 0.6, or an improvement (decrease) in the DAS28 of greater than 0.6 and less than or equal to 1.2 and attainment of a DAS28 of more than 5.1.
| percentage of participants | Placebo + MTX | Rituximab 2 x 0.5 g + MTX | Rituximab 2 x 1.0 g + MTX |
|---|---|---|---|
| No Response | 66.3 | 33.5 | 37.1 |
| Moderate Response | 29.1 | 49.1 | 51.2 |
| Good Response | 4.7 | 17.4 | 11.8 |
Sixty-six joints were assessed and classified as swollen/not swollen by pressure and joint manipulation on physical examination. The percentage change from baseline at each post-baseline visit was calculated as: \[(post-baseline value minus baseline value) divided by Baseline value\]\*100. A negative percentage change from baseline score indicates an improvement.
| percent change | Placebo + MTX | Rituximab 2 x 0.5 g + MTX | Rituximab 2 x 1.0 g + MTX |
|---|---|---|---|
| Week 24 [N=172, 166, 170] | -21.6 ± 65.82 | -47.4 ± 43.49 | -49.1 ± 38.59 |
| Week 48 [N=172, 166, 170] | -38.9 ± 66.83 | -54.0 ± 38.66 | -59.3 ± 37.04 |
Sixty-eight joints were assessed and classified as tender/not tender by pressure and joint manipulation on physical examination. The percentage change from baseline at each post-baseline visit was calculated as: \[(post-baseline value minus baseline value) divided by Baseline value\]\*100. A negative percentage change from baseline score indicates an improvement.
| percent change | Placebo + MTX | Rituximab 2 x 0.5 g + MTX | Rituximab 2 x 1.0 g + MTX |
|---|---|---|---|
| Week 24 [N=172, 166, 170] | -14.2 ± 69.20 | -42.5 ± 64.41 | -31.5 ± 66.52 |
| Week 48 [N=172, 166, 170] | -37.1 ± 55.08 | -50.2 ± 62.74 | -45.1 ± 62.64 |
The participant's overall assessment of their current disease activity measured on a 100 mm horizontal visual analog scale (VAS). The left-hand extreme of the line (0 mm) was described as "no disease activity" (symptom-free and no arthritis symptoms) and the right-hand extreme (100 mm) as "maximum disease activity" (maximum arthritis disease activity). The percentage change from baseline at each post-baseline visit was calculated as: \[(post-baseline value minus baseline value) divided by Baseline value\]\*100. A negative percentage change from baseline score indicates an improvement.
| percent change | Placebo + MTX | Rituximab 2 x 0.5 g + MTX | Rituximab 2 x 1.0 g + MTX |
|---|---|---|---|
| Week 24 [N=171, 166, 169] | -14.0 ± 48.94 | -31.5 ± 46.40 | -29.1 ± 54.43 |
| Week 48 [N=171, 166, 169] | -28.0 ± 50.78 | -39.7 ± 40.53 | -36.6 ± 47.60 |
The participant's assessment of their current level of pain on a 100 mm horizontal visual analog scale (VAS), where the left-hand extreme of the line (0 mm) was described as "no pain" and the right-hand extreme (100 mm) as "unbearable pain". The percentage change from baseline at each post-baseline visit was calculated as: \[(post-baseline value minus baseline value) divided by Baseline value\]\*100. A negative percentage change from baseline score indicates an improvement.
| percent change | Placebo + MTX | Rituximab 2 x 0.5 g + MTX | Rituximab 2 x 1.0 g + MTX |
|---|---|---|---|
| Week 24 [N=171, 166, 169] | -9.7 ± 52.58 | -25.7 ± 58.52 | -29.1 ± 53.11 |
| Week 48 [N=171, 166, 169] | -24.4 ± 60.22 | -35.5 ± 50.45 | -36.3 ± 47.87 |
The physician's assessment of the participant's current disease activity on a 100 mm horizontal VAS, where the left-hand extreme of the line (0 mm) was described as "no disease activity" (symptom-free and no arthritis symptoms) and the right-hand extreme (100 mm) as "maximum disease activity". The percentage change from baseline at each post-baseline visit was calculated as: \[(post-baseline value minus baseline value) divided by Baseline value\]\*100. A negative percentage change from baseline score indicates an improvement.
| percent change | Placebo + MTX | Rituximab 2 x 0.5 g + MTX | Rituximab 2 x 1.0 g + MTX |
|---|---|---|---|
| Week 24 [N=172, 166, 170] | -25.3 ± 38.52 | -36.9 ± 61.26 | -35.4 ± 46.99 |
| Week 48 [N=172, 166, 170] | -39.4 ± 39.95 | -40.5 ± 74.54 | -49.0 ± 40.01 |
The Stanford Health Assessment Questionnaire disability index is a patient-reported questionnaire specific for rheumatoid arthritis. It consists of 20 questions referring to eight domains: dressing/grooming, arising, eating, walking, hygiene, reach, grip, and daily activities. Participants choose from four response categories, ranging from 'without any difficulty' (Score=0) to 'unable to do' (Score=3). The overall score is the average of each of the 8 category scores and ranges from 0 to 3, where zero represents no disability and three very severe, high-dependency disability. The percentage change from baseline at each post-baseline visit was calculated as: \[(post-baseline value minus baseline value) divided by Baseline value\]\*100. A negative percentage change from baseline score indicates an improvement.
| percent change | Placebo + MTX | Rituximab 2 x 0.5 g + MTX | Rituximab 2 x 1.0 g + MTX |
|---|---|---|---|
| Week 24 [N=172, 165, 170] | -14.7 ± 38.41 | -26.9 ± 40.89 | -23.4 ± 49.52 |
| Week 48 [N=172, 165, 170] | -22.6 ± 39.63 | -30.2 ± 41.64 | -30.6 ± 39.95 |
C-Reactive Protein (CRP) was measured from blood samples by a central laboratory as a marker for inflammation. The percentage change from baseline at each post-baseline visit was calculated as: \[(post-baseline value minus baseline value) divided by Baseline value\]\*100. A negative percentage change from baseline score indicates an improvement.
| percent change | Placebo + MTX | Rituximab 2 x 0.5 g + MTX | Rituximab 2 x 1.0 g + MTX |
|---|---|---|---|
| Week 24 [N=172, 166, 170] | 58.1 ± 385.23 | -27.5 ± 84.36 | -23.1 ± 119.75 |
| Week 48 [N=172, 166, 170] | 40.1 ± 402.67 | -37.3 ± 94.65 | -34.9 ± 82.40 |
Erythrocyte sedimentation rate (ESR) indirectly measures how much inflammation is in the body. A higher ESR is indicative of increased inflammation. The percentage change from baseline at each post-baseline visit was calculated as: \[(post-baseline value minus baseline value) divided by Baseline value\]\*100. A negative percentage change from baseline score indicates an improvement.
| percent change | Placebo + MTX | Rituximab 2 x 0.5 g + MTX | Rituximab 2 x 1.0 g + MTX |
|---|---|---|---|
| Week 24 [N=172, 166, 169] | 8.0 ± 130.71 | -28.0 ± 42.20 | -29.2 ± 52.32 |
| Week 48 [N=172, 166, 169] | -14.5 ± 68.55 | -31.3 ± 49.72 | -36.7 ± 51.49 |
The SF-36 measures the impact of disease on overall quality of life and consists of 36 questions split into two major components: physical health and mental health. Under physical health are the following four domains: physical health, bodily pain, physical functioning and physical role limitations. Under the mental health domain there are four domains; mental health, vitality, social functioning, and emotional role limitation. The individual domain scores are aggregated to derive a physical-component summary score and a mental-component summary score which range from 0 to 100, with higher scores indicating a better level of functioning. The percentage change from baseline at each post-baseline visit was calculated as: \[(post-baseline value minus baseline value) divided by Baseline value\]\*100. A positive percentage change from baseline score indicates an improvement.
| percent change | Placebo + MTX | Rituximab 2 x 0.5 g + MTX | Rituximab 2 x 1.0 g + MTX |
|---|---|---|---|
| Physical Component: Week 24 [N=147, 152, 155] | 11.1 ± 27.63 | 23.7 ± 31.63 | 22.8 ± 33.09 |
| Physical Component: Week 48 [N=154, 154, 162] | 21.3 ± 30.99 | 26.4 ± 35.81 | 27.4 ± 31.93 |
| Mental Component: Week 24 [N=147, 152, 155] | 8.4 ± 29.43 | 12.6 ± 29.13 | 19.6 ± 56.64 |
| Mental Component: Week 48 [N=154, 154, 162] | 12.7 ± 30.52 | 18.4 ± 38.87 | 18.7 ± 57.34 |
The SF-36 measures the impact of disease on overall quality of life and consists of 36 questions in eight domains (physical function, pain, general and mental health, vitality, social function, physical and emotional health). The individual domain scores are calculated and transformed to range from 0 to 100, with higher scores indicating a better level of functioning. A positive change from baseline score indicates an improvement.
| scores on a scale | Placebo + MTX | Rituximab 2 x 0.5 g + MTX | Rituximab 2 x 1.0 g + MTX |
|---|---|---|---|
| Week 24 [N=138, 154, 155] | 2.078 ± 7.3032 | 3.532 ± 8.2747 | 3.866 ± 9.2154 |
| Week 48 [N=137, 148, 147] | 4.214 ± 8.2352 | 4.165 ± 9.5894 | 4.362 ± 8.1242 |
The SF-36 measures the impact of disease on overall quality of life and consists of 36 questions in eight domains (physical function, pain, general and mental health, vitality, social function, physical and emotional health). The individual domain scores are calculated and transformed to range from 0 to 100, with higher scores indicating a better level of functioning. A positive change from baseline score indicates an improvement.
| scores on a scale | Placebo + MTX | Rituximab 2 x 0.5 g + MTX | Rituximab 2 x 1.0 g + MTX |
|---|---|---|---|
| Week 24 [N=138, 152, 156] | 3.304 ± 8.5631 | 6.931 ± 8.2254 | 7.604 ± 8.5238 |
| Week 48 [N=137, 147, 147] | 8.449 ± 9.3543 | 8.079 ± 9.5435 | 8.964 ± 8.9890 |
The SF-36 measures the impact of disease on overall quality of life and consists of 36 questions in eight domains (physical function, pain, general and mental health, vitality, social function, physical and emotional health). The individual domain scores are calculated and transformed to range from 0 to 100, with higher scores indicating a better level of functioning. A positive change from baseline score indicates an improvement.
| scores on a scale | Placebo + MTX | Rituximab 2 x 0.5 g + MTX | Rituximab 2 x 1.0 g + MTX |
|---|---|---|---|
| Week 24 [N=138, 154, 154] | 3.553 ± 8.4181 | 5.460 ± 8.3099 | 5.653 ± 9.6817 |
| Week 48 [N=137, 148, 146] | 6.212 ± 9.6882 | 6.778 ± 8.7117 | 6.854 ± 9.3833 |
The SF-36 measures the impact of disease on overall quality of life and consists of 36 questions in eight domains (physical function, pain, general and mental health, vitality, social function, physical and emotional health). The individual domain scores are calculated and transformed to range from 0 to 100, with higher scores indicating a better level of functioning. A positive change from baseline score indicates an improvement.
| scores on a scale | Placebo + MTX | Rituximab 2 x 0.5 g + MTX | Rituximab 2 x 1.0 g + MTX |
|---|---|---|---|
| Week 24 [N=136, 153, 156] | 2.713 ± 8.7263 | 5.618 ± 9.0459 | 5.175 ± 8.8018 |
| Week 48 [N=137, 148, 147] | 6.423 ± 9.6752 | 6.812 ± 9.8633 | 6.497 ± 8.4820 |
The SF-36 measures the impact of disease on overall quality of life and consists of 36 questions in eight domains (physical function, pain, general and mental health, vitality, social function, physical and emotional health). The individual domain scores are calculated and transformed to range from 0 to 100, with higher scores indicating a better level of functioning. A positive change from baseline score indicates an improvement.
| scores on a scale | Placebo + MTX | Rituximab 2 x 0.5 g + MTX | Rituximab 2 x 1.0 g + MTX |
|---|---|---|---|
| Week 24 [N=137, 153, 156] | 3.278 ± 8.6850 | 2.770 ± 9.9943 | 4.486 ± 9.4930 |
| Week 48 [N=135, 147, 147] | 3.890 ± 8.7493 | 4.583 ± 10.5625 | 4.224 ± 9.9831 |
The SF-36 measures the impact of disease on overall quality of life and consists of 36 questions in eight domains (physical function, pain, general and mental health, vitality, social function, physical and emotional health). The individual domain scores are calculated and transformed to range from 0 to 100, with higher scores indicating a better level of functioning. A positive change from baseline score indicates an improvement.
| scores on a scale | Placebo + MTX | Rituximab 2 x 0.5 g + MTX | Rituximab 2 x 1.0 g + MTX |
|---|---|---|---|
| Week 24 [N=137, 154, 156] | 3.631 ± 8.7662 | 4.230 ± 9.3631 | 5.910 ± 9.5802 |
| Week 48 [N=135, 147, 147] | 6.853 ± 9.8221 | 5.925 ± 10.1495 | 5.869 ± 9.6168 |
The SF-36 measures the impact of disease on overall quality of life and consists of 36 questions in eight domains (physical function, pain, general and mental health, vitality, social function, physical and emotional health). The individual domain scores are calculated and transformed to range from 0 to 100, with higher scores indicating a better level of functioning. A positive change from baseline score indicates an improvement.
| scores on a scale | Placebo + MTX | Rituximab 2 x 0.5 g + MTX | Rituximab 2 x 1.0 g + MTX |
|---|---|---|---|
| Week 24 [N=138, 154, 156] | 2.529 ± 9.6435 | 5.985 ± 10.2986 | 6.468 ± 10.8868 |
| Week 48 [N=137, 148, 147] | 6.569 ± 10.6674 | 7.112 ± 11.5329 | 6.159 ± 11.0244 |
The SF-36 measures the impact of disease on overall quality of life and consists of 36 questions in eight domains (physical function, pain, general and mental health, vitality, social function, physical and emotional health). The individual domain scores are calculated and transformed to range from 0 to 100, with higher scores indicating a better level of functioning. A positive change from baseline score indicates an improvement.
| scores on a scale | Placebo + MTX | Rituximab 2 x 0.5 g + MTX | Rituximab 2 x 1.0 g + MTX |
|---|---|---|---|
| Week 24 [N=136, 151, 155] | 1.829 ± 11.5405 | 4.634 ± 11.6419 | 4.464 ± 13.6883 |
| Week 48 [N=137, 146, 146] | 4.724 ± 12.2649 | 6.257 ± 12.9640 | 4.446 ± 13.4036 |
The FACIT-Fatigue questionnaire is a self-administered patient questionnaire that consists of 13 questions designed to measure the degree of fatigue experienced by participants in the previous 7 days. Participants respond to the questions using a value in the range of 0 (not at all) to 4 (very much). The scale score is computed by summing the item scores, after reversing those items that are worded in the negative direction. The FACIT-Fatigue subscale score ranges from 0 to 52, where higher scores represent less fatigue. A positive change from baseline score indicates an improvement.
| scores on a scale | Placebo + MTX | Rituximab 2 x 0.5 g + MTX | Rituximab 2 x 1.0 g + MTX |
|---|---|---|---|
| Week 24 [N=170, 165, 168] | 2.661 ± 9.5093 | 5.564 ± 9.7438 | 6.398 ± 10.2143 |
| Week 48 [N=170, 165, 169] | 5.506 ± 10.9651 | 6.269 ± 9.7495 | 6.203 ± 9.7833 |
The DAS28 is a composite score to measure disease activity in patients with rheumatoid arthritis, derived from the following variables: * The number of swollen and tender joints assessed using the 28-joint count; * Erythrocyte sedimentation rate (ESR); * Patient's global assessment of disease activity measured on a 100 mm visual analog scale. The DAS28 score ranges from zero to ten. DAS28 above 5.1 indicates high disease activity. Low disease activity is defined by a DAS28 score less than or equal to 3.2. Remission is defined by a DAS28 score less than 2.6.
| percentage of participants | Placebo + MTX | Rituximab 2 x 0.5 g + MTX | Rituximab 2 x 1.0 g + MTX |
|---|---|---|---|
| Low Disease Activity | 4.7 | 17.5 | 12.4 |
| Clinical Remission | 2.3 | 9.6 | 9.4 |
The Stanford Health Assessment Questionnaire disability index is a patient-reported questionnaire specific for rheumatoid arthritis. It consists of 20 questions referring to eight domains: dressing/grooming, arising, eating, walking, hygiene, reach, grip, and daily activities. Participants choose from four response categories, ranging from 'without any difficulty' (Score=0) to 'unable to do' (Score=3). The overall score is the average of each of the 8 category scores and ranges from 0 to 3, where zero represents no disability and three very severe, high-dependency disability. A negative change from baseline score indicates an improvement. Improved HAQ-DI is defined as a change from Baseline score less than or equal to -0.22. An Unchanged HAQ-DI is defined as a change from Baseline score greater than -0.22 and less than 0.22. A worsened HAQ-DI score is defined as a change from Baseline score of greater than or equal to 0.22.
| percentage of participants | Placebo + MTX | Rituximab 2 x 0.5 g + MTX | Rituximab 2 x 1.0 g + MTX |
|---|---|---|---|
| Improved | 47.7 | 66.1 | 58.2 |
| No change | 32.6 | 23.6 | 32.4 |
| Worsened | 19.8 | 10.3 | 9.4 |
The Stanford Health Assessment Questionnaire disability index is a patient-reported questionnaire specific for rheumatoid arthritis. It consists of 20 questions referring to eight domains: dressing/grooming, arising, eating, walking, hygiene, reach, grip, and daily activities. Participants choose from four response categories, ranging from 'without any difficulty' (Score=0) to 'unable to do' (Score=3). The overall score is the average of each of the 8 category scores and ranges from 0 to 3, where zero represents no disability and three very severe, high-dependency disability. A negative change from baseline score indicates an improvement. Improved HAQ-DI is defined as a change from Baseline score less than or equal to -0.22. An Unchanged HAQ-DI is defined as a change from Baseline score greater than -0.22 and less than 0.22. A worsened HAQ-DI score is defined as a change from Baseline score of greater than or equal to 0.22.
| percentage of participants | Placebo + MTX | Rituximab 2 x 0.5 g + MTX | Rituximab 2 x 1.0 g + MTX |
|---|---|---|---|
| Improved | 54.7 | 73.3 | 68.8 |
| No change | 29.1 | 17.0 | 25.3 |
| Worsened | 16.3 | 9.7 | 5.9 |
A EULAR response reflects an improvement in disease activity and an attainment of a lower degree of disease activity based on the DAS-28 score. A Good Response is defined as an improvement (decrease) in the DAS28 of more than 1.2 compared with Baseline and attainment of a DAS28 score less than or equal to 3.2. A Moderate Response is defined as either: * an improvement (decrease) in the DAS28 of greater than 0.6 and less than or equal to 1.2 and attainment of a DAS28 score of less than or equal to 5.1 or, * an improvement (decrease) in the DAS28 of more than 1.2 and attainment of a DAS28 score of greater than 3.2. No Response is defined as either an improvement (decrease) in the DAS28 of less than or equal to 0.6, or an improvement (decrease) in the DAS28 of greater than 0.6 and less than or equal to 1.2 and attainment of a DAS28 score of 5.1 or higher.
| percentage of participants | Placebo + MTX | Rituximab 2 x 0.5 g + MTX | Rituximab 2 x 1.0 g + MTX |
|---|---|---|---|
| No Response | 41.3 | 26.9 | 31.8 |
| Moderate Response | 41.9 | 53.3 | 47.6 |
| Good Response | 16.9 | 19.8 | 20.6 |
The DAS28 is a composite score to measure disease activity in patients with rheumatoid arthritis, derived from the following variables: * The number of swollen and tender joints assessed using the 28-joint count; * Erythrocyte sedimentation rate (ESR); * Patient's global assessment of disease activity measured on a 100 mm visual analog scale. The DAS28 score ranges from zero to ten. DAS28 above 5.1 indicates high disease activity. Low disease activity is defined by a DAS28 score less than or equal to 3.2. Remission is defined by a DAS28 score less than 2.6.
| percentage of participants | Placebo + MTX | Rituximab 2 x 0.5 g + MTX | Rituximab 2 x 1.0 g + MTX |
|---|---|---|---|
| Low Disease Activity | 18.1 | 20.0 | 24.3 |
| Clinical Remission | 7.0 | 9.1 | 11.2 |
To achieve an ACR50 required at least a 50% improvement compared with Baseline in both tender joint counts (68 joints assessed for tenderness) and swollen joint counts (66 joints assessed for swelling), as well as a 50% improvement in three of the following five additional measurements: * Physician's global assessment of disease activity (assessed using a 100 mm Visual Analog Scale \[VAS\]); * Patient's global assessment of disease activity (assessed using a 100 mm VAS); * Patient's assessment of pain (assessed using a 100 mm VAS); * Health Assessment Questionnaire (HAQ; a patient completed questionnaire consisting of 20 questions, scored from 0-3); * Acute phase reactant: C-reactive protein (CRP) or, if CRP was missing, erythrocyte sedimentation rate (ESR). Participants who withdrew prematurely from the study prior to week 48, who received rescue therapy or had insufficient data in order to calculate a clinical response were considered to be non-responders.
| percentage of participants | Placebo + MTX | Rituximab 2 x 0.5 g + MTX | Rituximab 2 x 1.0 g + MTX |
|---|---|---|---|
| Percentage of Participants With an ACR50 Response at Week 48 | 18.6 | 32.9 | 34.1 |
To achieve an ACR70 required at least a 70% improvement compared with baseline in both tender joint counts (68 joints assessed for tenderness) and swollen joint counts (66 joints assessed for swelling), as well as a 70% improvement in three of the following five additional measurements: * Physician's global assessment of disease activity (assessed using a 100 mm Visual Analog Scale \[VAS\]); * Patient's global assessment of disease activity (assessed using a 100 mm VAS); * Patient's assessment of pain (assessed using a 100 mm VAS); * Health Assessment Questionnaire (HAQ; a patient completed questionnaire consisting of 20 questions, scored from 0-3); * Acute phase reactant: C-reactive protein (CRP) or, if CRP was missing, erythrocyte sedimentation rate (ESR). Participants who withdrew prematurely from the study prior to Week 48, who received rescue therapy or had insufficient data in order to calculate a clinical response were considered to be non-responders.
| percentage of participants | Placebo + MTX | Rituximab 2 x 0.5 g + MTX | Rituximab 2 x 1.0 g + MTX |
|---|---|---|---|
| Percentage of Participants With an ACR70 Response at Week 48 | 9.3 | 12.6 | 13.5 |
Peripheral CD19+ B-cell repletion was defined as a CD19+ B-cell count that returned to the Baseline value or returned to ≥ the lower limit of normal, whichever was lower.
| Weeks | Rituximab 2 x 0.5 g + MTX | Rituximab 2 x 1.0 g + MTX |
|---|---|---|
| Time to Repletion of Peripheral CD19+ B-cells | 110.3 (89.6 to 148.3) | 109.6 (94.1 to 134.9) |
A low immunoglobulin concentration was defined as a concentration below the lower level of normal.
| Percentage of participants | Rituximab + MTX |
|---|---|
| Pre-Rituximab (N=490) | 0.2 |
| Post-Rituximab (N=491) | 5.1 |
Collected over Up to 5.1 years after last dose in treatment period (treatment period = up to 5 years). Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Placebo + MTX | — | 16/172 (9.3%) | 112/172 (65.1%) |
| Rituximab 2 x 0.5 g + MTX | — | 52/167 (31.1%) | 149/167 (89.2%) |
| Rituximab 1.0 g + MTX | — | 46/170 (27.1%) | 151/170 (88.8%) |
| Switch Population: Placebo + MTX | — | 12/155 (7.7%) | 99/155 (63.9%) |
| Switch Population: Rituximab | — | 45/155 (29%) | 131/155 (84.5%) |
| Rituximab 2 x 0.5 g + MTX - Extended Safety Follow-up Period | — | 8/82 (9.8%) | 5/82 (6.1%) |
| Rituximab 2 x 1.0 g + MTX - Extended Safety Follow-up Period | — | 2/44 (4.5%) | 2/44 (4.5%) |
| Event | Placebo + MTX | Rituximab 2 x 0.5 g + MTX | Rituximab 1.0 g + MTX | Switch Population: Placebo + MTX | Switch Population: Rituximab | Rituximab 2 x 0.5 g + MTX - Extended Safety Follow-up Period | Rituximab 2 x 1.0 g + MTX - Extended Safety Follow-up Period |
|---|---|---|---|---|---|---|---|
| OsteoarthritisMusculoskeletal and connective tissue disorders | 1/172 | 4/167 | 5/170 | 1/155 | 0/155 | 0/82 | 0/44 |
| FallInjury, poisoning and procedural complications | 1/172 | 4/167 | 3/170 | 0/155 | 3/155 | 0/82 | 0/44 |
| Myocardial infarctionCardiac disorders | 0/172 | 4/167 | 0/170 | 0/155 | 0/155 | 0/82 | 0/44 |
| PneumoniaInfections and infestations | 1/172 | 3/167 | 4/170 | 1/155 | 3/155 | 1/82 | 0/44 |
| Angina pectorisCardiac disorders | 0/172 | 0/167 | 1/170 | 0/155 | 1/155 | 0/82 | 1/44 |
| HypoglycaemiaMetabolism and nutrition disorders | 0/172 | 0/167 | 0/170 | 0/155 | 0/155 | 0/82 | 1/44 |
| Coronary artery diseaseCardiac disorders | 2/172 | 3/167 | 1/170 | 2/155 | 3/155 | 0/82 | 0/44 |
| Cerebrovascular accidentNervous system disorders | 1/172 | 0/167 | 0/170 | 1/155 | 3/155 | 1/82 | 0/44 |
| Urinary tract infectionInfections and infestations | 0/172 | 3/167 | 1/170 | 0/155 | 1/155 | 0/82 | 0/44 |
| CellulitisInfections and infestations | 0/172 | 3/167 | 1/170 | 0/155 | 0/155 | 0/82 | 0/44 |
| Event | Placebo + MTX | Rituximab 2 x 0.5 g + MTX | Rituximab 1.0 g + MTX | Switch Population: Placebo + MTX | Switch Population: Rituximab | Rituximab 2 x 0.5 g + MTX - Extended Safety Follow-up Period | Rituximab 2 x 1.0 g + MTX - Extended Safety Follow-up Period |
|---|---|---|---|---|---|---|---|
| Upper respiratory tract infectionInfections and infestations | 13/172 | 59/167 | 50/170 | 13/155 | 39/155 | 0/82 | 0/44 |
| Infusion related reactionInjury, poisoning and procedural complications | 33/172 | 59/167 | 59/170 | 28/155 | 39/155 | — | — |
| Rheumatoid arthritisMusculoskeletal and connective tissue disorders | 30/172 | 49/167 | 36/170 | 26/155 | 31/155 | — | — |
| NasopharyngitisInfections and infestations | 17/172 | 43/167 | 42/170 | 16/155 | 34/155 | 0/82 | 0/44 |
| Urinary tract infectionInfections and infestations | 12/172 | 41/167 | 25/170 | 9/155 | 34/155 | 5/82 | 2/44 |
| SinusitisInfections and infestations | 6/172 | 24/167 | 21/170 | 6/155 | 29/155 | 0/82 | 0/44 |
| HypertensionVascular disorders | 3/172 | 28/167 | 18/170 | 2/155 | 15/155 | — | — |
| BronchitisInfections and infestations | 3/172 | 27/167 | 25/170 | 2/155 | 24/155 | 0/82 | 0/44 |
| DiarrhoeaGastrointestinal disorders | 7/172 | 27/167 | 20/170 | 7/155 | 20/155 | — | — |
| Back painMusculoskeletal and connective tissue disorders | 3/172 | 22/167 | 14/170 | 3/155 | 10/155 | — | — |
Safety population included all randomized participants who received any part of an infusion.
| Age, Continuous(years) | Placebo + MTX | Rituximab 2 x 0.5 g + MTX | Rituximab 2 x 1.0 g + MTX | Total |
|---|---|---|---|---|
| Mean | 52.16 ± 12.39 | 51.91 ± 12.93 | 51.30 ± 12.64 | 51.80 ± 12.64 |
| Sex: Female, Male(Participants) | Placebo + MTX | Rituximab 2 x 0.5 g + MTX | Rituximab 2 x 1.0 g + MTX | Total |
|---|---|---|---|---|
| Female | 147 | 133 | 138 | 418 |
| Male | 25 | 34 | 32 | 91 |
No study locations are listed for this record.
The record gives a start of Oct 2005, a primary completion of Jun 2008 and a completion of Jul 2013. It does not say whether these dates are actual or estimated.
Results were first posted in Jun 2013, 5 years after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Mar 2017. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Methotrexate · Rituximab